Global Bleeding Disorders Treatment Market Size study & Forecast, by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), by Drug Class (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressi

Global Bleeding Disorders Treatment Market Size study & Forecast, by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), by Drug Class (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others) and Regional Analysis, 2022-2029

Global Bleeding Disorders Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bleeding Disorders are a group of disorders that affect body’s ability to form proper blood clot. Its symptoms include excessive bleeding after injury, surgery, mensuration among others. Moreover, this improper clotting is mainly caused by defects in blood components such as platelets and/or clotting proteins. Bleeding disorders are generally caused by low red blood cell count, a vitamin K deficiency and side effects from certain medications. The increasing prevalence of Hemophilia and growing government initiatives for disease awareness are key factors driving the market growth.

Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. Its prevalence has progressively increased during the last few decades. According to the Centers for Disease Prevention and Control (CDC) estimates – the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 U.S. males for hemophilia A and 3.7 cases per 100,000 U.S. males for hemophilia B. Additionally, around 30,000 and 33,000 males are living with hemophilia in the country. Moreover, as per The Hemophilia Society – in UK, one in 2,000 men, women and children have a diagnosed bleeding disorder. Additionally, most common is von Willebrand disorder (VWD), which affects around 7,071 women and 4,081 men in the country. Also, rising healthcare investment in developing regions and growing digital transformation in health care sector would create lucrative growth prospectus for the market over the forecast period. However, the high cost of Bleeding Disorders Treatment and dearth of skilled professionals stifle market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bleeding Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing awareness towards bleeding disorders in the region.

Major market player included in this report are:
Novo Nordisk A/S
Baxter International Inc.
Alnylam Pharmaceuticals, Inc.
Pfizer, Inc.
Xenetic Biosciences, Inc.
Bristol-Myers Squibb Company
Sanofi S.A.
Amgen, Inc.
Janssen Global Services, LLC.
Bioverativ, Inc.

Recent Developments in the Market:
 In November 2022, CSL Behring LLC’s Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have experienced recent or past life-threatening haemorrhage, or have experienced repeated, severe spontaneous bleeding episodes.

Global Bleeding Disorders Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Drug Class, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Drug Class
Plasma-derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Novo Nordisk A/S
Baxter International Inc.
Alnylam Pharmaceuticals, Inc.
Pfizer, Inc.
Xenetic Biosciences, Inc.
Bristol-Myers Squibb Company
Sanofi S.A.
Amgen, Inc.
Janssen Global Services, LLC.
Bioverativ, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.